Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

NCT ID: NCT05374447

Last Updated: 2025-09-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-10

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will compare endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) with intranodal forceps biopsy (EBUS-IFB) as it relates to the rate of diagnosis of suspected sarcoidosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is prospective, single center randomized comparative study to determine the diagnostic yield and specimen quality of endobronchial ultrasound guided intranodal forceps biopsy of patients with suspected sarcoidosis based solely on imaging. This will be a single group study and will compare transbronchial needle aspiration via 19 or 21-gauge needle with intranodal forceps biopsy.

The study aims to answer a knowledge gap a as to whether the diagnostic yield and specimen quality of EBUS-TBNA with a 19G needle is less than those obtained by 1.9mm or greater intranodal forceps biopsy. The study proposed here will add to the field by further elucidating whether this procedure is beneficial for the diagnosis as it pertains to suspected sarcoidosis.

The anticipated required enrollment is 55 patients to achieve an α of 0.05 and β of 0.2. This assumes an unassisted diagnostic yield of 62.5% with standard of care EBUS-TBNA as reported in Ray et al, and a diagnostic supplementation to 80% yield with intranodal forceps biopsies.

References

1. Oki, M., Saka, H., \& Sako, C. (2004). Bronchoscopic miniforceps biopsy for mediastinal nodes. Journal of Bronchology \& Interventional Pulmonology, 11(3), 150-153.
2. Herth FJ, Morgan RK, Eberhardt R, Ernst A. Endobronchial ultrasound-guided miniforceps biopsy in the biopsy of subcarinal masses in patients with low likelihood of non-small cell lung cancer. Ann Thorac Surg. 2008 Jun; 85(6):1874-8.
3. Chrissian A, Misselhorn D, Chen A. Endobronchial-ultrasound guided miniforceps biopsy of mediastinal and hilar lesions. The Annals of Thoracic Surgery. 2011;92(1):284-288.
4. Franke KJ, Bruckner C, Szyrach M, Ruhle KH, Nilius G, Theegarten D. The contribution of endobronchial ultrasound-guided forceps biopsy in the diagnostic workup of unexplained mediastinal and hilar lymphadenopathy. Lung. 2012;190(2):227-232.
5. Herth FJF, Schuler H, Gompelmann D, et al. Endobronchial ultrasound-guided lymph node biopsy with transbronchial needle forceps: a pilot study. European Respiratory Journal. 2012;39(2):373-377.
6. Darwiche K, Freitag L, Nair A, et al. Evaluation of a novel endobronchial ultrasound-guided lymph node forceps in enlarged mediastinal lymph nodes. Respiration. 2013;86(3):229-236.
7. Ray AS, Li C, Murphy TE, et al. Improved diagnostic yield and specimen quality with endobronchial ultrasound-guided forceps biopsies: a retrospective analysis. The Annals of Thoracic Surgery. 2020;109(3):894-901

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mediastinal Lymphadenopathy Sarcoidosis, Pulmonary Mediastinal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

1:1 randomization to EBUS-TBNA alone or EBUS-TBNA and EBUS-IFB
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants
The participant will be blinded to which group they were randomized to.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EBUS-TBNA

These will be the patient who undergo EBUS-TBNA only without EBUS-IFB

Group Type ACTIVE_COMPARATOR

Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy

Intervention Type PROCEDURE

Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.

EBUS-TBNA + EBUS-IFB

These will be the individuals who undergo EBUS-TBNA followed by EBUS-IFB in the same procedure

Group Type EXPERIMENTAL

Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy

Intervention Type PROCEDURE

Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy

Patients with mediastinal adenopathy will undergo EBUS-IFB and EBUS-TBNA during the same procedure to compare the yield of this procedure with EBUS-TBNA alone.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EBUS-IFB

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Radiologic evidence of mediastinal and/or hilar lymphadenopathy
* Attending radiologist or pulmonologist reports a possible diagnosis of sarcoidosis
* Age 18 years or older

Exclusion Criteria

These are the characteristics that a participant must NOT have in order to be eligible to participate in the study.

Order Number Criteria

* Severe pulmonary hypertension
* Inability to undergo general anesthesia
* Severe coagulopathy or bleeding diathesis
* Previously diagnosed sarcoidosis
* Patient presently taking clopidogrel
* Patient deemed to be high risk for general anesthesia per anesthesiologist
* Hemodynamic instability
* Mediastinitis
* Acute Hypercarbic Respiratory Failure (pCO2 \>55mmHg)
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

George Washington University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Khalil Diab

MD - Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mardi Gomberg, MD

Role: STUDY_DIRECTOR

The George Washington University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The George Washington University Hospital

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Khalil Diab, MD

Role: CONTACT

2027412180

Benjamin Delprete, DO

Role: CONTACT

2027412180

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Khalil Diab, MD

Role: primary

2027412180

Benjamin Delprete, DO

Role: backup

2027412180

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCR224078

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

EBUS-TBNA Versus EBUS-TBNB
NCT01467635 WITHDRAWN NA